LUNG NON-SMALL CELL SQUAMOUS CARCINOMA
Clinical trials for LUNG NON-SMALL CELL SQUAMOUS CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG NON-SMALL CELL SQUAMOUS CARCINOMA trials appear
Sign up with your email to follow new studies for LUNG NON-SMALL CELL SQUAMOUS CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost lung cancer survival
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone…
Matched conditions: LUNG NON-SMALL CELL SQUAMOUS CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:35 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tests a new combination of drugs (berzosertib, carboplatin, gemcitabine, and pembrolizumab) in people with advanced squamous non-small cell lung cancer who have not had chemotherapy before. The goal is to find the best dose and see if the combination helps control the …
Matched conditions: LUNG NON-SMALL CELL SQUAMOUS CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC